Pexelizumab
Indications
- Adjunct in Percutaneous Intervention for ST Elevation Myocardial Infarction (STEMI) (see Coronary Artery Disease, [[Coronary Artery Disease]])
- APEX Trial (JAMA, 2007) [MEDLINE]: pexelizumab did not impact mortality rate (mortality rate was low in the trial)
Pharmacology
- Humanized monoclonal antibody that binds the C5 component of complement
Metabolism
Administration
Dose Adjustment
Adverse Effects
Other Adverse Effects
References
- Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007 Jan 3;297(1):43-51 [MEDLINE]